WAYLAND, Mass, JULY 17, 2018 /PRNewswire/ -- Candela
Corporation, a leading global aesthetic device company, announces
the U.S. Food and Drug Administration (FDA) clearance of its Vbeam®
Prima, an advanced 595 nm pulsed dye laser (PDL). With the addition
of a 1064 nm wavelength and a number of other new features, the
Vbeam Prima will be able to effectively treat a broad range of skin
conditions, including: rosacea, port wine stains, acne, facial, leg
and spider veins, scars, benign pigmented lesions and wrinkles,
warts, stretch marks and photo aging.
"Building on the strong heritage of Vbeam, which has provided
life changing aesthetic and dermatologic benefits for millions of
patients for more than 20 years, the FDA clearance of the Vbeam
Prima represents a step forward in the treatment of vascular and
pigmented skin conditions. This important milestone exemplifies
Candela's mission of continuous innovation based on
scientifically proven technologies, consistent clinical
results and a trusted partnership with both patients and our
medical practitioners. Under new ownership and new
management, we are recommitting to scientific leadership,
real-world clinical results and long term partnerships with our
customers," states Geoffrey Crouse,
Chief Executive Officer of Candela.
The Vbeam is a highly efficient PDL used by healthcare providers
all over the world to treat a variety of indications for both face
and body with high patient tolerability and a low incidence of side
effects. The Vbeam has been long considered a "gold standard" for
the device based treatment of rosacea, and has also been
successfully used for the treatment of port wine stains and
vascular anomalies in infants, as well as adults. The Vbeam is
currently used in nearly 700 universities and hospitals worldwide,
and has been included in hundreds of medical publications. The new
Vbeam Prima builds on that legacy of success by offering advanced
features that will help physicians and their patients achieve
better results, along with an improved treatment experience.
"In a clinical study using Vbeam Prima, facial redness and
rosacea symptoms were dramatically reduced after 4 treatments,"
said Dr. Eric Bernstein, MD, M.S.E.,
Director of Laser Surgery & Cosmetic Dermatology at the Main
Line Center for Laser Surgery in Ardmore,
PA, an investigational site for the device. "I've worked
with the Vbeam platform for years, and I am extremely excited about
advancements with the Prima, especially the 50% greater power
enabling a 15 mm spot size, both contact and spray cooling,
once-a-day calibration and extended dye life thanks to a completely
re-designed system," he added.
For more information about the Vbeam Prima, please
visit https://syneron-candela.com/na/prima
Candela
Candela is a leading global aesthetic device company with an
extensive product portfolio and a global distribution footprint.
The Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications
including body contouring, hair removal, wrinkle reduction, tattoo
removal, women's intimate wellness treatments, improving the skin's
appearance through the treatment of superficial benign vascular and
pigmented lesions, and the treatment of acne, leg veins and
cellulite. In addition to Vbeam, Candela has a wide portfolio of
trusted, leading products including CO2RE,
CO2RE Intima, Profound, elōs Plus, the Gentle series,
PicoWay, UltraShape and VelaShape. Acquired by Apax Partners in
2017, the Company markets, services and supports its products in 86
countries. It has offices in the
United States, Australia,
Canada, China, France, Germany, Hong
Kong, Israel, Italy, Japan,
Portugal, Spain and the United
Kingdom and many international distributors.
Media Contact:
EvolveMKD
P: 646.517.4220 | E: candela@evolvemkd.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/candela-announces-fda-clearance-of-vbeam-prima-300681997.html
SOURCE Candela